From candidate selection through to proof-of-concept
6 / 54 articles displayed
News
Quotient Sciences, a leading drug development services organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading, U.K., facility. The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels.
Growth
Quotient Sciences, announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa. The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial manufacturing.
News
We are delighted to be taking part in the MHRA / HRA Combined Ways of Working Pilot and on Friday 22 June 2018 made its first two pilot Phase I submissions.
News
Quotient Sciences announces that it has completed the integration and rebrand of Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.
News
The collaboration simplifies contracting and delivery by offering clients a single solution for an entire pediatric program, with only one contract and one PPD point of contact. As a result of that structure, the number of handoffs is significantly reduced and the process is much more streamlined, eliminating the delays that often occur when moving from early dosing to later phases.
Acquisition
Quotient Sciences announces it has acquired Pharmaterials, a CDMO based in Reading, UK. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint and further supports the growth of Quotient’s Translational Pharmaceutics platform.
